CA224-104

About this trial

This is a multicentre, phase 2 study in patients with non-small cell lung cancer. This study is looking at adding relatlimab (anti LAG-3 checkpoint inhibitor) to nivolumab plus chemotherapy and comparing it to nivolumab plus chemotherapy. The objective of the trial is to confirm the dose safety of these drugs when combined and to compare the progression free survival.

Patient Profile

Participants with previously untreated Stage IV Non-Small Cell Lung Cancer.

Where’s this trial being run?

Beaumont Hospital

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

For more detailed information

Questions?

Here’s a list of questions you may have for your doctor or local cancer research team.


Summary Data

Name: CA224-104
Number: 21-12
Full Title:

A Phase 2 Randomized Double-blind Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

Principal Investigator: Dr Jarushka Naidoo
Type: Industry Sponsored
Sponsor:

Bristol-Myers Squibb

Recruitment Started: Global: 15-Feb-2021
Ireland: 30-Jul-2021
Global Recruitment Target: 520
Ireland Recruitment Target: 6